Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2Observational 1

Sponsor

Conditions

Breast Neoplasms 4997Neoplasms 4192Prostatic Neoplasms 2426Carcinoma, Non-Small-Cell Lung 2261Colorectal Neoplasms 2050Lung Neoplasms 1703Multiple Myeloma 1454Lymphoma 1403Leukemia, Myeloid, Acute 1379Neoplasm Metastasis 1372Melanoma 1269Pancreatic Neoplasms 1200Leukemia 1194Ovarian Neoplasms 1190Lymphoma, Non-Hodgkin 1128Precursor Cell Lymphoblastic Leukemia-Lymphoma 1088Head and Neck Neoplasms 1055Leukemia, Lymphocytic, Chronic, B-Cell 994Lymphoma, Follicular 896Colonic Neoplasms 893Brain Neoplasms 875Stomach Neoplasms 854Recurrence 848Carcinoma, Hepatocellular 845Glioblastoma 837Lymphoma, Large B-Cell, Diffuse 770Rectal Neoplasms 758Uterine Cervical Neoplasms 725Carcinoma, Renal Cell 704Hodgkin Disease 696

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × Glaucoma × Clear all
NCT04947124 2025-01-20

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Qlaris Bio, Inc.

Phase 2 Completed
3 enrolled

Glaucoma, Hydrophthalmos, Ocular Hypertension, Sturge-Weber Syndrome

NCT05495269 2025-01-20

Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)

Qlaris Bio, Inc.

Phase 2 Completed
2 enrolled

Glaucoma, Ocular Hypertension, Sturge-Weber Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡